Evidence map›Paper›PMID 33849822›Full record

ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2021

[LIM-domain binding protein 2 regulated by m

D Zhai, G Wang, L Li, X Jia, G Zheng, J Yin

Open access · greenAbstract read
In one paragraph

Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

D ZhaiCancer Research Institute, Affiliated Cancer Hospital of Guangzhou Medical University//Guangzhou Key Laboratory of Translational Medicine on Cancer Treatment, Guangzhou 510095, China.
G WangCancer Research Institute, Affiliated Cancer Hospital of Guangzhou Medical University//Guangzhou Key Laboratory of Translational Medicine on Cancer Treatment, Guangzhou 510095, China.
L LiCancer Research Institute, Affiliated Cancer Hospital of Guangzhou Medical University//Guangzhou Key Laboratory of Translational Medicine on Cancer Treatment, Guangzhou 510095, China.
X JiaCancer Research Institute, Affiliated Cancer Hospital of Guangzhou Medical University//Guangzhou Key Laboratory of Translational Medicine on Cancer Treatment, Guangzhou 510095, China.
G ZhengCancer Research Institute, Affiliated Cancer Hospital of Guangzhou Medical University//Guangzhou Key Laboratory of Translational Medicine on Cancer Treatment, Guangzhou 510095, China.
J YinCancer Research Institute, Affiliated Cancer Hospital of Guangzhou Medical University//Guangzhou Key Laboratory of Translational Medicine on Cancer Treatment, Guangzhou 510095, China.
Guangzhou Medical University Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the role and expression pattern of LIM-domain binding protein 2 (LDB2) in lung adenocarcinoma.

objectiveWe studied the expression pattern of LDB2 in lung adenocarcinoma based on data from the online databases TCGA, GEO and CPTAC, and the results were verified in lung adenocarcinoma tissues and cells using immunohistochemistry, qRT-PCR and Western blotting. The relationship between LDB2 and the prognosis of patients with lung adenocarcinoma was analyzed using GEPIA and GEO databases. We further analyzed the role of LDB2 in regulating cell behaviors in a H1299 cell model over-expressing LDB2 using cell counting, soft agar colony forming assay and flow cytometry. The m

objectiveLDB2 expression was significantly decreased in lung adenocarcinoma in comparison with normal tissues based on data from TCGA, GEPIA and CPTAC, and the same results were obtained from 80 lung adenocarcinoma tissues and 17 adjacent normal tissues. Similarly, LDB2 expression was decreased in lung adenocarcinoma cells as compared with 16HBE cells. The data from Prognoscan and GEPIA suggested that a high LDB2 expression was positively correlated with a more favorable outcome of lung adenocarcinoma patients. LDB2-overexpressing H1299 cells showed a significant inhibition of proliferative activity with cell cycle arrest in S phage. Bioinformatics analysis and MeRIP-qPCR assay confirmed the presence of m

objectiveLDB2 expression can be up-regulated by m

Indexed as

Adenocarcinoma of LungLung NeoplasmsCarrier ProteinsCell ProliferationGene Expression Regulation, NeoplasticHumansLIM Domain ProteinsRNA HelicasesTranscription FactorsCarrier ProteinsLDB2 protein, humanLIM Domain ProteinsRNA HelicasesTranscription FactorsYTHDC2 protein, humanLIM-domain binding protein 2lung adenocarcinomaN6-methyladenosineproliferation

Identifiers

PMID33849822
PMCPMC8075788
OpenAlexW3154429618

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.